Your shopping cart is empty

Subscriber login

REGISTER FOR FREE EZINES

Advanced Search

Return to the main site

Home
Books
Conferences
DVDs
Newsletters
Form 483s
Pharma Quality Advisor
Webinar Training Pass
White Papers
Advertising/Sponsorships
About Us

E-Zines

Check out our free and informative ezines and sign up now

Home > Newsletters > FDAnews Drug Daily Bulletin > UK Court: AstraZeneca’s Seroquel XR Patent Invalid

FDAnews Drug Daily Bulletin

March 26, 2012 | Vol. 9 No. 60

UK Court: AstraZeneca’s Seroquel XR Patent Invalid

A British court has ruled that AstraZeneca’s patent on an extended-release version of its blockbuster antidepressant drug Seroquel is invalid, the company said Thursday.
Businessweek

Register Now
Print This Page
Email This Article
RSS
Archives

Related Articles

Pharma Blog Watch Distributor’s Threat on Drug Deliveries Breakup of Physician, Drug Company Relationship Could Improve Healthcare, Cut Cost European Pharmacist Organizations Call for Action By Governments to Tackle Shortages

Home
Advertising/Sponsorships
About Us
Contact Us
Site Map
Privacy Policy

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.

ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnews

All rights reserved. Do not duplicate or redistribute in any form.